Lee's Pharmaceutical Holdings Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	9.5yrs
Board average tenure	10.9yrs

Recent management updates

Recent updates

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29

What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

Jan 12

Have Insiders Sold Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Recently?

Dec 22

Don't Ignore The Fact That This Insider Just Sold Some Shares In Lee's Pharmaceutical Holdings Limited (HKG:950)

Dec 08

Is Lee's Pharmaceutical Holdings Limited's (HKG:950) Recent Price Movement Underpinned By Its Weak Fundamentals?

Dec 01

Is Lee's Pharmaceutical Holdings Limited (HKG:950) A Strong Dividend Stock?

Nov 18

CEO

Lee's Pharmaceutical Holdings has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Siu Fong Lee	Chairman & Compliance Officer	no data	HK$12.18m	0.14% HK$ 856.9k
Xiaoyi Li	Founder	3yrs	HK$6.54m	9.99% HK$ 62.9m
Wanee Leelalertsuphakun	MD, Chief Marketing & Sales Officer and Executive Director	20.6yrs	HK$13.20m	1.31% HK$ 8.2m
Yiu Ming Chow	Group CFO & Company Secretary	9.5yrs	no data	no data
Yueshen Chen	Director of Administration in China	no data	no data	no data
Tsui Victor Kailok	Group Chief Manufacturing Officer	12.3yrs	no data	no data
Yuanjue Sun	Chief Medical Officer	2.6yrs	no data	no data
Zhongyu Jiao	Group Deputy GM & GM of the Risk Control Centre	no data	no data	no data

9.5yrs

Average Tenure

60yo

Average Age

Experienced Management: 950's management team is seasoned and experienced (9.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Siu Fong Lee	Chairman & Compliance Officer	no data	HK$12.18m	0.14% HK$ 856.9k
Xiaoyi Li	Founder	no data	HK$6.54m	9.99% HK$ 62.9m
Wanee Leelalertsuphakun	MD, Chief Marketing & Sales Officer and Executive Director	no data	HK$13.20m	1.31% HK$ 8.2m
James Gale	Non-Executive Director	2.3yrs	HK$300.00k	no data
Yau Ching Chan	Independent Non-Executive Director	22.3yrs	HK$216.00k	0.088% HK$ 556.4k
Wah Keung Tsim	Independent Non-Executive Director	19.6yrs	HK$216.00k	0.051% HK$ 321.0k
Yee Wah Cheang	Independent Non Executive Director	less than a year	HK$135.00k	no data

10.9yrs

Average Tenure

64yo

Average Age

Experienced Board: 950's board of directors are seasoned and experienced ( 10.9 years average tenure).

Lee's Pharmaceutical Holdings Management

Management criteria checks 2/4

Key information

Recent management updates

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Board Member recently bought HK$123k worth of stock

Board Member recently bought HK$75k worth of stock

Board Member recently bought HK$50k worth of stock

Board Member recently bought HK$113k worth of stock

Recent updates

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Board Member recently bought HK$123k worth of stock

New minor risk - Market cap size

Board Member recently bought HK$75k worth of stock

Investor sentiment improves as stock rises 15%

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Board Member recently bought HK$50k worth of stock

Board Member recently bought HK$113k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock

Investor sentiment improves as stock rises 17%

Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock

Investor sentiment improves as stock rises 18%

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

New minor risk - Market cap size

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Upcoming dividend of HK$0.01 per share at 1.3% yield

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Price target decreased to HK$1.80

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022

Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa

Price target decreased to HK$1.80

Upcoming dividend of HK$0.01 per share

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022

Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Board Member recently bought HK$231k worth of stock

Lee's Pharmaceutical Holdings Limited Announces That Teglutik Obtains Drug Registration Certificate

Board Member recently bought HK$381k worth of stock

First quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.07 in 1Q 2021)

Lee's Pharmaceutical Holdings Limited's Natulan Obtains Drug Registration Certificate

Upcoming dividend of HK$0.031 per share

Lee's Pharmaceutical Holdings Limited to Report Q1, 2022 Results on May 26, 2022

Price target decreased to HK$4.85

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: HK$3.38 (vs HK$0.22 in FY 2020)

Lee's Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022

Price target decreased to HK$5.30

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Lee's Pharmaceutical Holdings Limited Obtains Approval from the Center for Drug Evaluation

Second quarter 2021 earnings released: EPS HK$3.59 (vs HK$0.097 in 2Q 2020)

Investor sentiment deteriorated over the past week

Non-Executive Director Simon Miles Ball has left the company

Price target decreased to HK$6.42

First quarter 2021 earnings released: EPS HK$0.07 (vs HK$0.068 in 1Q 2020)

Price target decreased to HK$6.92

Upcoming dividend of HK$0.031 per share

Lee's Pharmaceutical Holdings Limited Announces Sodium Phenylbutyrate Granules Obtained Approval for Drug Registration

Full year 2020 earnings released: EPS HK$0.22 (vs HK$0.21 in FY 2019)

Does Lee's Pharmaceutical Holdings (HKG:950) Have A Healthy Balance Sheet?

Full year 2020 earnings released: EPS HK$0.22 (vs HK$0.21 in FY 2019)